FCGR2B and breast cancer: Therefore, the reduced susceptibility of sensitive BC cells to CD32-CR T cell activity by the anti-CD18 mAb is likely to be due at least in part to the blockade of the interaction of β2 integrins on T cells (Bui et al, 2020) with ICAM1 leading to the inhibition of CD32-CR T-cell cytotoxicity.